Acrivon Therapeutics Inc.... (ACRV)
NASDAQ: ACRV
· Real-Time Price · USD
1.36
-0.03 (-2.16%)
At close: Aug 15, 2025, 3:08 PM
Acrivon Therapeutics Common Stock Income Statement
Financials in USD. Fiscal
year is
undefined.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 |
Revenue | 848K | 848K | 848K | 1.88M | 1.88M | 1.88M | 1.88M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 914K | 1.11M | 1.03M | 873K | 904K | 999K | 1.09M | 1.25M | 1.22M | 1.19M | 1.09M | 782K | 743K | 484K | 261K | 261K |
Gross Profit | -187K | -387K | -300K | -873K | -904K | -999K | -1.09M | -1.25M | -1.22M | -1.19M | -1.09M | -782K | -743K | -484K | -261K | -261K |
Operating Income | -94.41M | -93.19M | -89.2M | -85.3M | -76.3M | -70.38M | -67.1M | -55.99M | -49.43M | -39.84M | -32.66M | -26.98M | -20.08M | -14.15M | -6.94M | -2.67M |
Interest Income | 8.79M | 9.75M | 9.2M | 6.84M | 5.91M | 4.98M | 5.34M | 5.34M | 3.58M | 1.81M | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -85.96M | -83.75M | -80.56M | -76.98M | -69M | -64.12M | -60.39M | -50.06M | -44.8M | -36.7M | -31.17M | -26.58M | -19.82M | -14M | -6.78M | -2.44M |
Net Income | -85.96M | -83.75M | -80.56M | -76.98M | -69M | -64.12M | -58.75M | -47.41M | -41.77M | -33.57M | -29.68M | -26.18M | -19.57M | -13.85M | -6.63M | -2.21M |
Selling & General & Admin | 25.32M | 25.26M | 25.21M | 24.46M | 24.19M | 22.77M | 21.21M | 19.72M | 15.35M | 12.2M | 8.71M | 5.84M | 4.66M | 2.82M | 1.67M | 455K |
Research & Development | 68.79M | 67.63M | 63.47M | 60.47M | 51.48M | 46.98M | 45.49M | 36.02M | 34.08M | 27.64M | 23.95M | 21.14M | 15.41M | 11.34M | 5.27M | 2.22M |
Other Expenses | -311K | -511K | -200K | -200K | -200K | 1.61M | 3.24M | 4.26M | 4.64M | 3.13M | 1.49M | 474K | 328K | 223K | 231K | 231K |
Operating Expenses | 93.79M | 92.38M | 88.47M | 84.72M | 75.47M | 69.75M | 66.7M | 55.74M | 49.43M | 39.84M | 32.66M | 26.98M | 20.08M | 14.15M | 6.94M | 2.67M |
Interest Expense | n/a | n/a | n/a | 1.64M | 1.64M | 1.64M | 1.64M | n/a | n/a | n/a | 8K | 81K | 81K | 81K | 73K | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 71.76M | 93.19M | 89.2M | 85.3M | 76.3M | 70.38M | 67.1M | 55.99M | 49.43M | 39.84M | 32.66M | 26.98M | 20.08M | 14.15M | 6.94M | 2.67M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | 6.92K | -1.63M | -2.65M | -3.02M | -3.13M | -1.49M | -401K | -255K | -150K | -158K | -231K |
Shares Outstanding (Basic) | 38.46M | 38.35M | 38.24M | 38.11M | 36.13M | 22.59M | 22.34M | 22.08M | 21.97M | 21.92M | 20.88M | 18.81M | 12.91M | 12.91M | 12.91M | 12.91M |
Shares Outstanding (Diluted) | 38.46M | 38.35M | 38.24M | 38.11M | 36.13M | 22.59M | 22.34M | 22.08M | 21.97M | 21.92M | 20.88M | 18.81M | 12.91M | 12.91M | 12.91M | 12.91M |
EPS (Basic) | -2.25 | -2.22 | -2.44 | -2.7 | -2.77 | -2.88 | -2.66 | -2.18 | -1.99 | -1.8 | -1.85 | -1.81 | -1.51 | -1.07 | -0.51 | -0.17 |
EPS (Diluted) | -2.25 | -2.22 | -2.44 | -2.7 | -2.77 | -2.88 | -2.66 | -2.18 | -1.99 | -1.8 | -1.85 | -1.81 | -1.51 | -1.07 | -0.51 | -0.17 |
EBITDA | -93.85M | -83.77M | -79.55M | -75.8M | -65.05M | -68M | -64.95M | -53.87M | -49.19M | -39.52M | -32.12M | -26.56M | -19.76M | -13.92M | -6.92M | -2.66M |
EBIT | -69.77M | -82.57M | -80.56M | -76.66M | -65.98M | -68.71M | -65.43M | -54.32M | -49.43M | -39.84M | -32.66M | -26.98M | -20.08M | -14.15M | -6.94M | -2.67M |
Depreciation & Amortization | 914K | 1.14M | 1.05M | 901K | 932K | 999K | 1.09M | 1.25M | 1.22M | 1.19M | 1.09M | 795K | 756K | 497K | 274K | 261K |